Biocon Biologics and Viatris get CHMP Nod for Abevmy
Bevacizumab inhibits the formation of tumor vasculature, thereby inhibiting tumor growth
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Biocon Biologics
Biocon Biologics partners with IDF to improve access to insulins
The partnership coincides with the start of the centenary celebrations of the discovery of insulin
Biocon Biologics and Viatris get EC Approval for Kixelle, biosimilar insulin Aspart
Kixelle, a fast-acting insulin analog indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1…
Biocon Biologics to offer its Oncology Biosimilars through Cancer Access Partnership in over 30…
Biocon Biologics, a subsidiary of
Biocon has signed an agreement with the Clinton Health Access Initiative (CHAI) to expand…
Biocon Biologics inducts Professor Peter Piot to its Board as Independent Director
Professor Piot is the Director of the London School of Hygiene & Tropical Medicine and the Handa Professor of Global Health
Abu Dhabi firm, ADQ invests Rs 555 crores in Biocon Biologics
Biocon Biologics had raised over $255 million from global investors from Jan to Nov 2020
USFDA defers action on BLA for Avastin biosimilar, notifies Biocon Biologics, Mylan
To complete the application, the agency noted that an inspection of the manufacturing facility is required as a part of the…
Biocon Biologics signs MoU with CSSC in Tanzania for Mission 10 cents, affordable insulins programme
The programme is expected to roll-out early next year
Biocon Biologics, Mylan get CHMP recommendation for approval of biosimilar insulin Aspart
The European Commission decision on the approval is expected early next year
Biocon Biologics gets Rs 1, 125 cr capital injection from Goldman Sachs
Goldman Sachs will be issued Optionally Convertible Debentures at a post money equity valuation of $3.94 billion